short acting glp 1 Short‐acting glucagon‐like peptide‐1 receptor agonists as add‐on to insulin therapy in type diabetes: A review - Albèr - 2017 - Diabetes, Obesity and Metabolism GLP-1 for Diabetes vs GLP-1

But how does a weight loss drug trigger this

Edwin Kuffner, McNeil's medical director, had prepared for the meeting by attending some 100 practice sessions with a consulting company that specialized in readying corporate clients to speak before the FDA, according to a court deposition

This makes it a systemic glow support product not a spot treatment

10.1093/oxfordjournals.bmb.a072259 33 EyreD

Known as the incretin effect, GLP-1 and its synergetic sister hormone glucose-dependent insulinotropic polypeptide (GIP), are rapidly released by lower enteroendocrine L-cells (GLP-1) or upper enteroendocrine K-cells (GIP) in the gut following food intake and rising circulatory glucose levels to augment the glucose-stimulated release of insulin by pancreatic cells

Shelly, B